Trial 9L-17-3


An Open-Label, Non-Randomized, Multicenter Phase I Study to Determine The Maximum Tolerated and /or Recommended Phase II Dose of Oral Mutant IDH1 (mIDH1) Inhibitor BAY 1436032 and to Characterize its Safety, tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Efficacy in Patients with mIDH1-R132X Advanced Acute Myeloid Leukemia (AML)

Type: Treatment
Phase: Phase I
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic, Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Mojtaba Akhtari, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, John Lee, D.M., Suraj Chandwani, D.M., Anastasia Philabaum, Coordinator, Christine Duran, Coordinator, Donna Fernando, R.N., Meena Ibrahim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.